Evidence map›Paper›PMID 42890693›Full record

ReviewFrontiers in immunology2026

Lung microbiota, gut microbiota, and the lung-gut axis in lung cancer immunotherapy: a tripartite regulatory perspective.

Qin Chen, Jing Wang, Daqiang Sun, Jianwen Qin

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qin ChenDepartment of Respiratory and Critical Medicine, Tianjin Chest Hospital, Tianjin, China.
Jing WangTianjin Key Laboratory of Cancer Prevention and Therapy, Department of Thoracic Oncology, Tianjin Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China.
Daqiang SunDepartment of Thoracic Surgery, Tianjin Chest Hospital, Tianjin, China.
Jianwen QinDepartment of Respiratory and Critical Medicine, Tianjin Chest Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiota is well established as a key modulator of systemic immunity, with growing evidence supporting its impact on lung cancer immunotherapy outcomes. However, the contributions of the lung microbiota and the recently recognized intratumoral microbiota remain less defined. This review synthesizes current evidence on the gut-lung axis, consolidating the tripartite regulatory network of gut, lung, and intratumoral microbiota in shaping the lung cancer immune microenvironment and immunotherapy response. We discuss how gut-derived metabolites such as indole-3-propionic acid may remotely modulate CD8

Indexed as

Gastrointestinal MicrobiomeImmunotherapyLungLung NeoplasmsMicrobiotaAnimalsHumansTumor Microenvironmentgut microbiotaimmunotherapyintratumoral microbiotalung cancerlung-gut axislung microbiota

Identifiers

PMID42890693
PMCPMC13673961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.